- Home
- ZTEK vs SWKH Comparison
ZTEK vs SWKH Comparison
Compare ZTEK & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZTEK
- SWKH
- Stock Information
- Founded
- ZTEK 2008
- SWKH 1996
- Country
- ZTEK Canada
- SWKH United States
- Employees
- ZTEK N/A
- SWKH N/A
- Industry
- ZTEK Major Chemicals
- SWKH Diversified Financial Services
- Sector
- ZTEK Industrials
- SWKH Finance
- Exchange
- ZTEK Nasdaq
- SWKH Nasdaq
- Market Cap
- ZTEK 165.9M
- SWKH 179.1M
- IPO Year
- ZTEK N/A
- SWKH 1999
- Fundamental
- Price
- ZTEK $1.16
- SWKH $15.06
- Analyst Decision
- ZTEK
- SWKH Strong Buy
- Analyst Count
- ZTEK 0
- SWKH 1
- Target Price
- ZTEK N/A
- SWKH $18.00
- AVG Volume (30 Days)
- ZTEK 33.2K
- SWKH 17.4K
- Earning Date
- ZTEK 08-13-2025
- SWKH 08-14-2025
- Dividend Yield
- ZTEK N/A
- SWKH N/A
- EPS Growth
- ZTEK N/A
- SWKH 51.50
- EPS
- ZTEK N/A
- SWKH 1.41
- Revenue
- ZTEK $607,016.00
- SWKH $34,906,000.00
- Revenue This Year
- ZTEK N/A
- SWKH $52.93
- Revenue Next Year
- ZTEK N/A
- SWKH N/A
- P/E Ratio
- ZTEK N/A
- SWKH $10.67
- Revenue Growth
- ZTEK 2826.26
- SWKH 18.02
- 52 Week Low
- ZTEK $0.50
- SWKH $12.00
- 52 Week High
- ZTEK $1.84
- SWKH $16.24
- Technical
- Relative Strength Index (RSI)
- ZTEK 30.38
- SWKH 59.21
- Support Level
- ZTEK $1.03
- SWKH $14.56
- Resistance Level
- ZTEK $1.16
- SWKH $15.28
- Average True Range (ATR)
- ZTEK 0.10
- SWKH 0.33
- MACD
- ZTEK -0.03
- SWKH 0.04
- Stochastic Oscillator
- ZTEK 17.02
- SWKH 78.57
About ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About SWKH SWK Holdings Corporation
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.